Clinical Trials
7 trialsNCT03841617 2026-05-20
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT03244956 2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT06440850 2026-02-02
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
City of Hope Medical Center
Phase 2 Recruiting
NCT05668962 2024-12-12
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
Massachusetts General Hospital
Phase 2 Recruiting
NCT04447183 2023-10-23
DTC
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2 Unknown
NCT00085293 2018-11-29
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
National Cancer Institute (NCI)
Phase 2 Completed
NCT00181168 2018-11-02
Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
Johns Hopkins University
Phase 2 Completed